[go: up one dir, main page]

WO1998000538A3 - Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization - Google Patents

Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization Download PDF

Info

Publication number
WO1998000538A3
WO1998000538A3 PCT/IB1997/000814 IB9700814W WO9800538A3 WO 1998000538 A3 WO1998000538 A3 WO 1998000538A3 IB 9700814 W IB9700814 W IB 9700814W WO 9800538 A3 WO9800538 A3 WO 9800538A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
peptides
coupled receptors
peptidomimetic compounds
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1997/000814
Other languages
French (fr)
Other versions
WO1998000538A2 (en
Inventor
Michel Bouvier
Michael Dennis
Terence E Hebert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Biosignal Inc
Original Assignee
Universite de Montreal
Biosignal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal, Biosignal Inc filed Critical Universite de Montreal
Priority to AU37050/97A priority Critical patent/AU3705097A/en
Priority to EP97933814A priority patent/EP0910640A2/en
Publication of WO1998000538A2 publication Critical patent/WO1998000538A2/en
Publication of WO1998000538A3 publication Critical patent/WO1998000538A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to peptides and peptidomimetic compounds that modulate the function of G-protein-coupled receptors by affecting the ratio of receptor monomer to homo-oligomeric forms. Novel short peptides of a preferred length of up to about 15-20 amino acid residues are modeled on transmembrane domains of G-protein-coupled receptors, whose activities are affected by the formation of oligomers. These novel peptides and peptidomimetic compounds can be used to selectively affect the activity of G-protein-coupling receptors, thereby functioning as potential therapeutic drugs, etc.. A preferred peptide is GIIMGTFTLCWLPFFIVNIV.
PCT/IB1997/000814 1996-07-01 1997-07-01 Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization Ceased WO1998000538A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU37050/97A AU3705097A (en) 1996-07-01 1997-07-01 Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization
EP97933814A EP0910640A2 (en) 1996-07-01 1997-07-01 Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2103196P 1996-07-01 1996-07-01
US60/021,031 1996-07-01

Publications (2)

Publication Number Publication Date
WO1998000538A2 WO1998000538A2 (en) 1998-01-08
WO1998000538A3 true WO1998000538A3 (en) 1998-05-07

Family

ID=21801930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/000814 Ceased WO1998000538A2 (en) 1996-07-01 1997-07-01 Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization

Country Status (4)

Country Link
EP (1) EP0910640A2 (en)
AU (1) AU3705097A (en)
CA (2) CA2259132A1 (en)
WO (1) WO1998000538A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000715A2 (en) * 1996-07-01 1998-01-08 Biosignal Inc. Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization
US6555522B1 (en) 1998-02-05 2003-04-29 Mount Sinai School Of Medicine Of The City Of New York Peptides and other small molecules derived from regions of interacting proteins and uses thereof
ES2299242T3 (en) * 1998-02-27 2008-05-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services ANTAGONISTS OF PROTEIN G.
US7105488B1 (en) 1998-02-27 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services G protein-coupled receptor antagonists
AU6941000A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
US7304127B2 (en) 1999-08-27 2007-12-04 United States Of America As Represented By The Secretary, Department Of Health And Human Services Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
US20010053848A1 (en) * 2000-03-10 2001-12-20 Patel Yogesh C. Hetero-oligomeric G protein-coupled receptors as novel drug targets
EP2336169A1 (en) * 2000-04-21 2011-06-22 New England Medical Center Hospital G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
RU2430113C2 (en) 2004-11-04 2011-09-27 Тафтс Медикал Сентер, Инк. Chimeric polypeptide selectively reacting with related chemokine receptor, pharmaceutical composition and application of chimeric polypeptide (versions)
JP7517986B2 (en) 2017-12-19 2024-07-17 ジーピーシーアール セラピューティクス，インク． GPCR heteromeric inhibitors and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008160A1 (en) * 1989-01-20 1990-07-26 Imperial Cancer Research Technology Ltd. Growth factor receptor-like peptides without tyrosine-kinase activity
WO1994005695A1 (en) * 1992-09-10 1994-03-17 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
WO1994024162A1 (en) * 1993-04-21 1994-10-27 Vetigen NUCLEOTIDE SEQUENCES CODING FOR THE BOVINE β3-ADRENERGIC RECEPTOR, AND APPLICATIONS THEREOF
WO1997035881A2 (en) * 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
WO1997040148A2 (en) * 1996-04-22 1997-10-30 L'universite De Montreal Peptide antagonists derived from the transmembrane domains of g protein-coupled receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008160A1 (en) * 1989-01-20 1990-07-26 Imperial Cancer Research Technology Ltd. Growth factor receptor-like peptides without tyrosine-kinase activity
WO1994005695A1 (en) * 1992-09-10 1994-03-17 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
WO1994024162A1 (en) * 1993-04-21 1994-10-27 Vetigen NUCLEOTIDE SEQUENCES CODING FOR THE BOVINE β3-ADRENERGIC RECEPTOR, AND APPLICATIONS THEREOF
WO1997035881A2 (en) * 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
WO1997040148A2 (en) * 1996-04-22 1997-10-30 L'universite De Montreal Peptide antagonists derived from the transmembrane domains of g protein-coupled receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GREGORY, H. ET AL.: "Luteinizing hormone release from dissociated pituitary cells by dimerization of occupied LHRH receptors.", NATURE, vol. 300, 18 November 1982 (1982-11-18), pages 269 - 271, XP002057464 *
HEBERT T E ET AL: "A PEPTIDE DERIVED FROM A BETA2-ADRENERGIC RECEPTOR TRANSMEMBRANE DOMAIN INHIBITS BOTH RECEPTOR DIMERIZATION AND ACTIVATION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 27, 5 July 1996 (1996-07-05), pages 16384 - 16392, XP002045155 *
WAGNER T ET AL: "DIFFERENTIAL REGULATION OF G-PROTEIN ALPHA-SUBUNIT GTPASE ACTIVITY BY PEPTIDES DERIVED FROM THE THIRD CYTOPLASMIC LOOP OF THE ALPHA2-ADRENERGIC RECEPTOR", FEBS LETTERS, vol. 365, no. 1, 1995, pages 13 - 17, XP002045148 *

Also Published As

Publication number Publication date
CA2259132A1 (en) 1998-01-08
EP0910640A2 (en) 1999-04-28
CA2205543A1 (en) 1998-01-01
WO1998000538A2 (en) 1998-01-08
AU3705097A (en) 1998-01-21

Similar Documents

Publication Publication Date Title
WO1998000538A3 (en) Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization
PT1288223E (en) DERIVATIVES OF THERAPEUTIC PEPTIDES
WO1997035881A3 (en) Receptor and transporter antagonists
WO2001081415A3 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
WO1997024436A3 (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
AU6162996A (en) Synthesis of conformationally restricted amino acids, peptides and peptidomimetics by catalytic ring closing metathesis
EA200200713A1 (en) SULPHONAMIDES AND THEIR DERIVATIVES, MODULATING ENDOTHELINE ACTIVITY
IS4962A (en) Parathyroid hormone analogues for the treatment of osteoporosis
Sluss et al. Inhibition of iodine-125-labeled human follitropin binding to testicular receptor by epidermal growth factor and synthetic peptides
AU682638B2 (en) Peptide, bronchodilator and blood flow ameliorant
WO1999042127A3 (en) Receptor derived peptides as modulators of receptor activity
ATE245168T1 (en) PEPTIDES THAT EXHIBIT ANTI-CELL ADHESION ACTIVITY
ES2180781T3 (en) NEW LEAGUES OF THE OPIACEO MU RECEIVER: AGONISTS AND ANTAGONISTS.
Li et al. Benextramine irreversibly inhibits [125I] neuropeptide Y affinity labeling of the Y2 binding protein in bovine hippocampus
WO1998000715A3 (en) Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization
WO1997040148A3 (en) Peptide antagonists derived from the transmembrane domains of g protein-coupled receptors
Knight et al. Cholecystokinin octapeptide analogues stable to brain proteolysis
WO1999025732A3 (en) Design of coiled-coil dimer derived antagonists of 4-helix bundle cytokine specific receptors
AU2003260306A1 (en) Bicyclic oligopeptides
Cascieri et al. Biochemical characterization of the quinuclidine antagonist binding site on the human NK1 receptor
CA2216704A1 (en) Novel peptides and remedy for bone diseases containing the same as active ingredient
AU3616899A (en) Peptide fragments of murine epidermal growth factor as laminin receptor targets
Huston Department zyxwvutsrqponmlkjih
IT1177963B (en) New active site peptide derivs.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2259132

Country of ref document: CA

Ref country code: CA

Ref document number: 2259132

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997933814

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98503951

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997933814

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09214175

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1997933814

Country of ref document: EP